IXJ News and Press, iShares Global Healthcare From 10/19/22

Summary Persistent inflation spurred the US Federal Reserve to raise interest rates aggressively in the third quarter, with 0.75% hikes in both July and September. Earnings estimates for equities had continued to climb during the early part of the year and only started to moderate...

Summary Earnings growth can happen in this ETF, which is supported by some insurance economics, but also simple demographics and resilient healthcare demand. Earnings growth is hard to come by in current markets, and can justify a substantial premium over the general market. H...

Summary We expect macro headwinds will continue to pressure U.S. corporate earnings in the coming months. We expect earnings expectations to decline as multinational firms realize foreign exchange headwinds that accelerated over the past year. Investors can avoid undue interna...

Summary With inflation at the highest level in decades and volatility continuing to surge, equity investors are questioning their next moves. At the beginning of the year, financial conditions were very loose by any means historically, and we've very rapidly moved from loose finan...

Summary Jackson Hole reset expectations to focus more on inflation. The U.S. dollar should stabilize over the medium-term amid hawkishness from other central banks and slowing economic data. At stake is Europe’s ability to refill their storage tanks ahead of winter. ...

Summary We believe that cash flow and debt sustainability are likely to become increasingly important as real economic growth slows and credit access tightens. Cash flow provides a link between a company’s income statement and their balance sheet. Focusing on the Russel...

Summary Today's market X-ray shows the returns for each index, asset class, sector, and so on, since the recent low point on June 16th. Of the global indices, US small caps are in the lead, followed by the NASDAQ. High beta stocks are the most preferred factors since June 16. ...

Summary The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry’s long-term financial performance. The legislation caps out-of-pocket costs for Medicare prescriptions at $2,000 per year, starting in 2025. ...

Why health care stocks may outperform the broader market in the long run. Is now the time to consider health care stocks? Why health care is still a good way for investors to play defense. Greg Bonnell: Many health care stocks are down from the highs put in e...

Johnson & Johnson offers investors a combination of dividend growth and capital appreciation upside potential. The company is home to some of the best brands in the consumer health care space, a robust pharmaceutical portfolio, and an expansive slate of medical technology offering...